bk
viru
detect
blood
urin
viru
first
appear
urin
viruria
detect
blood
viremia
sever
week
later
prefer
screen
test
transplant
center
blood
bk
quantit
viral
dna
polymeras
chain
reaction
pcr
sensit
serum
urin
bk
viral
test
specif
serum
test
versu
urin
test
bk
viremia
also
better
predictor
bk
nephropathi
altern
strategi
use
bk
viruria
screen
appear
earlier
bk
viremia
bk
viruria
present
clinician
consid
lower
immunosuppress
switch
bk
viremia
screen
recommend
screen
time
monthli
first
month
everi
month
month
post
transplant
bk
viral
load
greater
copi
strongli
associ
bk
nephropathi
bk
viruria
greater
copi
associ
bk
nephropathi
next
step
kidney
transplant
biopsi
gold
standard
confirm
diagnosi
see
degre
nephropathi
biopsi
remain
gold
standard
diagnosi
bkassoci
nephropathi
bk
viru
induc
number
characterist
chang
kidney
biopsi
includ
intranuclear
viral
inclus
tubular
injurytubul
tubulointerstiti
inflamm
none
kidney
biopsi
find
pathognomon
bkassoci
nephropathi
diagnosi
must
confirm
demonstr
antibodi
bk
immunohistochemistri
cytolog
examin
urin
detect
bkinfect
cell
decoy
cell
characterist
cell
enlarg
nuclei
singl
basophil
intranuclear
inclus
identif
decoy
cell
sensit
specif
diagnosi
bkassoci
nephropathi
goal
treat
bkassoci
nephropathi
erad
viru
maintain
kidney
function
prevent
acut
chronic
reject
treatment
bkassoci
nephropathi
involv
reduc
immunosuppress
permit
nativ
immunemedi
handl
bk
viru
possibl
strategi
includ
discontinu
singl
immunosuppress
agent
reduct
dosag
steroid
avoid
antivir
therapi
leflunomid
cidofovir
use
conjunct
decreas
immunosuppress
instanc
ivig
also
use
particularli
patient
concomit
acut
reject
patient
graft
failur
result
bk
nephropathi
retranspl
ye
transplant
nephrectomi
usual
indic
ideal
bk
viral
load
undetect
serum
pcr
time
transplant
cmv
member
genu
herpesviru
belong
famili
herpesvirida
compos
doublestrand
dna
genom
exposur
viru
indic
immunoglobulin
g
anticmv
antibodi
present
twothird
donor
recipi
prior
transplant
cmv
transmit
donor
either
blood
transfus
transplant
kidney
symptomat
cmv
infect
occur
transplant
recipi
signific
caus
morbid
mortal
risk
factor
associ
develop
cmv
infect
post
transplant
includ
lymphocytedeplet
induct
therapi
highdos
mmf
absenc
adequ
antivir
prophylaxi
group
highest
risk
cmv
infect
histor
group
cmv
donor
posit
cmv
recipi
neg
cmv
greatest
risk
sever
primari
infect
first
month
post
transplant
cmv
associ
atherosclerosi
chronic
allograft
reject
cmv
associ
sever
vascular
injuri
includ
transplant
glomerulopathi
hemolyt
urem
syndrom
thrombot
microangiopathi
transplant
renal
arteri
stenosi
cmv
infect
impli
detect
cmv
via
cultur
pcr
comparison
cmv
diseas
requir
clinic
sign
symptom
addit
viral
detect
clinic
sign
symptom
cmv
diseas
includ
fever
leukopenia
organ
involv
hepat
pneumon
coliti
chorioretin
etc
quantit
assess
viral
load
via
pcr
help
determin
clinic
phenotyp
cmv
dna
level
copiesmmg
total
dna
peripher
blood
correl
clinic
evid
diseas
two
strategi
cmv
prevent
antivir
prophylaxi
preemptiv
monitoringtherapi
antivir
prophylaxi
mean
give
valganciclovir
without
evid
cmv
infect
viremia
preemptiv
monitoringtherapi
mean
reserv
antivir
therapi
patient
develop
cmv
viremia
preemptiv
monitor
associ
lower
drug
cost
advers
toxic
howev
increas
laboratori
surveil
logist
labor
antivir
prophylaxi
hand
expens
put
patient
risk
drug
toxic
associ
decreas
reactiv
herpesviru
lower
rate
opportunist
infect
allograft
loss
drug
choic
prophylaxi
valganciclovir
durat
cmv
prophylaxi
depend
cmv
serolog
donor
recipi
last
month
other
last
month
ganciclovir
valganciclovir
commonli
use
agent
treatment
cmv
infect
drugi
must
dose
base
renal
function
valganciclovir
indic
patient
mild
moder
diseas
treatment
dose
normal
kidney
function
mg
twice
daili
dose
need
reduc
kidney
failur
ganciclovir
indic
sever
diseas
high
viral
load
question
gastrointestin
absorpt
treatment
usual
continu
viral
load
undetect
week
patient
switch
month
prophylact
therapi
viral
load
chang
appropri
dose
ganciclovir
week
ganciclovir
resist
assess
viral
genotyp
test
resist
discov
usual
strategi
increas
ganciclovir
dose
use
foscarnet
cidofovir
howev
nephrotox
aspect
treatment
care
reduct
immunosuppress
ebv
member
herpesviru
famili
one
common
human
virus
peopl
becom
infect
ebv
sometim
live
flourish
set
immunosuppress
associ
ptld
live
vaccin
contraind
transplant
administ
prior
live
vaccin
given
prior
transplant
patient
immunosuppress
therefor
transplant
minimum
week
inactiv
vaccin
given
post
transplant
time
frame
abl
receiv
vaccin
post
transplant
month
close
contact
also
appropri
vaccin
tabl
show
tabl
commonli
question
vaccin
inhal
influenza
vaccin
live
attenu
vaccin
contraind
patient
travel
abroad
consid
visit
travel
clinic
appropri
vaccin
prophylaxi
need
